Anti-CD19 CAR-T therapy (Phase 1/2 trial)

CD19-targeted chimeric antigen receptor T-cell · National Research Center for Hematology

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Anti-CD19 CAR-T therapy (Phase 1/2 trial), covering 2026-02-09 to 2026-02-09. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Patients With B-cell Lymphoproliferative Disorders [Phase 1, Phase 2]

See pricing